Clearwater Paper (CLW) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
16 Nov, 2025Executive summary
Net sales rose 14% year-over-year to $392 million in Q2 2025, driven by the Augusta acquisition and higher shipment volumes, partially offset by lower average pricing and product mix changes.
Net income from continuing operations was $4 million ($0.22 per diluted share), reversing a prior year loss, with improved cost performance and lower major maintenance expenses.
Adjusted EBITDA improved to $40 million (10.2%–10.3% margin), up from negative $8.6 million to $9 million last year, reflecting cost reductions and higher volumes.
The company completed the sale of its tissue operations in 2024; results are now reported as discontinued operations.
Focus remains on operational execution, cost reduction, and maintaining a strong balance sheet to support strategic options.
Financial highlights
Q2 2025 net sales: $392 million (up 14% year-over-year); first half net sales: $770 million (up 28%).
Net income from continuing operations: $4 million ($0.22/share) vs. $42 million loss ($2.50/share) year-over-year.
Adjusted EBITDA: $40 million (10.2%–10.3% margin); first half Adjusted EBITDA: $70 million.
SG&A expenses down nearly 14% year-over-year to 6.7% of net sales.
Paperboard sale volumes increased to 304,713 tons, up 12% year-over-year; average net selling price fell 3% to $1,182/ton.
Outlook and guidance
Q3 2025 Adjusted EBITDA expected in the $10 million–$20 million range, reflecting major maintenance outage costs and flat to slightly lower production volumes.
Full-year 2025 revenue expected at $1.5 billion–$1.6 billion, with $30 million–$40 million in cost savings and $80 million–$90 million in capital expenditures.
Utilization rates projected to remain in the mid-80% range for 2025.
Major maintenance costs of $45–$50 million expected for the year.
Recent U.S. tariff changes and new tax legislation are not expected to materially impact 2025 results.
Latest events from Clearwater Paper
- Major transformation, cost savings, and ESG progress drive 2026 proxy proposals and governance.CLW
Proxy Filing5 Mar 2026 - Net sales up 12%, Adjusted EBITDA at $107M, but goodwill impairment drove a net loss.CLW
Q4 202518 Feb 2026 - Q2 net sales up 12% but net loss; tissue sale to reduce debt and boost paperboard focus.CLW
Q2 20242 Feb 2026 - Augusta mill acquisition boosts scale and reach as high utilization supports strong margins.CLW
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Augusta acquisition and tissue sale drove higher sales, debt reduction, and a paperboard focus.CLW
Q4 202422 Jan 2026 - Q3 sales and volumes rose, but margins fell; $100M buyback and debt reduction followed tissue sale.CLW
Q3 202416 Jan 2026 - Q1 net sales up 46% to $378M, with cost savings and Augusta synergies driving EBITDA growth.CLW
Q1 202523 Dec 2025 - Major strategic shifts, robust governance, and strong ESG focus define this proxy cycle.CLW
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, executive pay, and stock plan amendment.CLW
Proxy Filing1 Dec 2025